We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04271956
Recruitment Status : Active, not recruiting
First Posted : February 17, 2020
Last Update Posted : February 23, 2023
Information provided by (Responsible Party):
German CLL Study Group

Brief Summary:
The aim of the CLL-RT1 trial is to evaluate the efficacy and safety of zanubrutinib (BGB-3111), a BTK inhibitor plus tislelizumab (BGB-A317), a PD1 inhibitor for treatment of patients with Richter Transformation

Condition or disease Intervention/treatment Phase
Richter Transformation Biological: Tislelizumab Drug: Zanubrutinib Phase 2

Detailed Description:
Richter Transformation (RT) remains one of the biggest challenges in the treatment and management of CLL. While considerable progress has been made in the treatment of CLL, the prognosis of CLL patients with malignant disease transformation still is very poor and reported median OS is between 6 to 8 months. Conventional approaches with chemo- and chemoimmunotherapy have largely failed to improve response rates in RT patients. However, as the established treatment approach for de-novo Diffuse Large B Cell Lymphoma (DLBCL) is chemoimmunotherapy with a combination of Rituximab, Cyclophosphamid, Hydroxydaunorubicin, Vincristin and Prednisolon (R-CHOP), this has become the most commonly used regimen for lack of alternative strategies, despite poor efficacy. Patients being fit enough for allogeneic transplantation are undergoing this procedure after induction with R-CHOP. However, the majority of patients are not suitable for transplantation and relapse quickly. Hence, there is urgent need to improve therapy of RT by testing new compounds and combinations for treatment of this disease. Based on the available preclinical and preliminary clinical data on checkpoint inhibition plus Bruton's tyrosine (BTK) inhibition, the current trial will systematically assess the safety and toxicity of tislelizumab, a programmed cell death protein 1 (PD-1) inhibitor, plus zanubrutinib, a BTK inhibitor in patients with RT.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 57 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of Zanubrutinib (BGB-3111), a BTK Inhibitor, Plus Tislelizumab (BGB-A317), a PD1 Inhibitor, for Treatment of Patients With Richter Transformation
Actual Study Start Date : February 19, 2020
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Tislelizumab + Zanubrutinib

Induction: 6 cycles (q21d) of Tislelizumab + Zanubrutinib

Consolidation: 6 cycles (q21d) of Tislelizumab + Zanubrutinib

Maintenance: Patients with response to therapy continue to take Tislelizumab + Zanubrutinib (Q3W) until disease progression, non-tolerance or when receiving allogeneic stem cell transplantation (SCT) for consolidation

Biological: Tislelizumab
Cycle (q21d): Day 1: Tislelizumab i.v. 200 mg
Other Name: BGB-A317

Drug: Zanubrutinib
Cycle (q21d): Zanubrutinib p.o. 160 mg twice a day
Other Name: BGB-3111

Primary Outcome Measures :
  1. Overall response rate (ORR) after induction therapy according to the refined Lugano Classification (Cheson et al, 2016) [ Time Frame: 18 weeks ]
    Proportion of patients having achieved complete response (CR) or partial response (PR)

Secondary Outcome Measures :
  1. ORR after induction therapy according to the IWCLL criteria (Hallek et al, 2018) [ Time Frame: 18 weeks ]
    Proportion of patients having achieved complete response (CR) or partial response (PR)

  2. ORR after consolidation therapy [ Time Frame: 36 weeks ]
    Proportion of patients having achieved complete response (CR) or partial response (PR)

  3. Progression-free Survival (PFS) [ Time Frame: Up to 15 months ]
    Time from the date of registration to the date of first occurrence of disease progression or relapse (determined according to the IWCLL guidelines and Lugano classification) or death from any cause, whichever occurs first

  4. Overall Survival (OS) [ Time Frame: Up to 15 months ]
    Time from the date of registration to the date of death due to any cause

  5. Time to Next Treatment (TTNT) [ Time Frame: Up to 15 months ]
    Time from date of registration to the date of first subsequent CLL/RT treatment

  6. Duration of response [ Time Frame: Up to 15 months ]

    Time from the date of first documented response to the first occurrence of progression, relapse or death by any cause, whichever occurs first.

    Duration of response will be evaluated both according to the refined Lugano Classification as well as according to the IWCLL criteria. In the first case it will be calculated for patients with CR or PR, in the second case for patients with (clin.) CR, (clin.) CRi, PR, or PR-L.

  7. Type, frequency, severity of adverse events (AEs) [ Time Frame: Up to 15 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed diagnosis of CLL according to iwCLL criteria (Hallek et al, 2018)
  2. Confirmed histopathological diagnosis of RT
  3. Creatinine clearance ≥30ml/min calculated according to the modified formula of Cockcroft and Gault or directly measured with 24hr urine collection
  4. Adequate liver function as indicated by a total bilirubin ≤ 2x, AST/ALT ≤ 2.5 x the institutional ULN value, unless directly attributable to the patient's CLL/RT or to Gilbert's Syndrome, in which case a max. total bilirubin ≤ 4 x and AST/ALT ≤ 5 x the institutional ULN value are required
  5. Negative serological testing for hepatitis B (HBsAg negative and anti-HBc negative; patients positive for anti-HBc may be included if PCR for HBV DNA is negative and HBV-DNA PCR is performed every two months until 2 months after last dose of zanubrutinib), negative testing for hepatitis-C RNA and negative HIV test within 6 weeks prior to registration
  6. Age at least 18 years
  7. ECOG performance status 0-2, ECOG 3 is only permitted if related to CLL or RT (e.g. due to anaemia or severe constitutional symptoms)
  8. Life expectancy ≥ 6 months
  9. Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements

Exclusion Criteria:

  1. Patients who did not respond to previous line of RT therapy (i.e. primary progressive patients)
  2. Patients with more than one prior line of RT therapy
  3. Allogenic stem cell transplantation within the last 100 days or signs of active graft-versus-host disease (GVHD) after prior allogeneic stem cell transplantation within any time
  4. Patients with confirmed progressive multifocal leukoencephalopathy (PML)
  5. Uncontrolled autoimmune condition
  6. Malignancies other than CLL currently requiring systemic therapies
  7. Active infection currently requiring systemic treatment
  8. Any comorbidity or organ system impairment rated with a Cumulative Illness Rating Scale (CIRS) score of 4, excluding the eyes/ears/nose/throat/larynx organ system, or any other life-threatening illness, medical condition or organ system dysfunction that - in the investigator´s opinion could comprise the patients safety or interfere with the absorption or metabolism of the study drugs
  9. Requirement of therapy with strong CYP3A4 inhibitors/inducers
  10. Requirement of therapy with phenprocoumon or other vitamin K antagonists.
  11. Use of investigational agents, e.g. monoclonal antibodies or other experimental drugs within clinical trials, which might interfere with the study drug within 28 days (or 5 times half-life [t1/2] of the compound, whichever is longer) prior to registration
  12. Known hypersensitivity to tislelizumab, zanubrutinib or any of the excipients
  13. Pregnant women and nursing mothers (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment)
  14. Fertile men or women of childbearing potential unless:

    • surgically sterile or ≥ 2 years after the onset of menopause, or
    • willing to use two methods of reliable contraception including one highly effective contraceptive method (Pearl Index <1) and one additional effective (barrier) method during study treatment and for 12 months after the end of study treatment.
  15. Vaccination with a live vaccine <28 days prior to randomization
  16. Legal incapacity
  17. Prisoners or subjects who are institutionalized by regulatory or court order
  18. Persons who are in dependence to the sponsor or an investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04271956

Layout table for location information
Allgemeines Krankenhaus der Stadt Wien
Vienna, Austria, 1090
Copenhagen, Denmark, 2100
Uniklinik Köln
Cologne, Germany, 50937
Universitätsklinikum Carl Gustav Carus
Dresden, Germany, 01307
Universitätsklinikum Essen
Essen, Germany, 45147
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, Germany, 24105
H.O.T Praxis Landshut
Landshut, Germany, 84036
Universitätsklinikum Magdeburg
Magdeburg, Germany, 39120
München Klinik Schwabing
Munich, Germany, 80804
Brüderkrankenhaus St. Josef Paderborn
Paderborn, Germany, 33098
Universitätsmedizin Rostock
Rostock, Germany, 18057
Universitätsklinik Ulm
Ulm, Germany, 89081
Sponsors and Collaborators
German CLL Study Group
Layout table for investigator information
Principal Investigator: Barbara Eichhorst, Prof. Department I of Internal Medicine, University Hospital Cologne
Additional Information:
Layout table for additonal information
Responsible Party: German CLL Study Group
ClinicalTrials.gov Identifier: NCT04271956    
Other Study ID Numbers: CLL-RT1
First Posted: February 17, 2020    Key Record Dates
Last Update Posted: February 23, 2023
Last Verified: February 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action